Stock listing
Milestone Pharmaceuticals Inc.
Selected listing: MIST · NASDAQ · USD · US
Milestone Pharmaceuticals Inc. (NASDAQ:MIST), Health Technology. Latest release Sep 3, 2026: Milestone Pharmaceuticals Announces NMPA Approval of Etripamil…
- Ticker
- NASDAQ:MIST
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- NASDAQ
- Currency
- USD
About Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc. is a public company traded under the ticker MIST in the American market. Milestone focuses on developing innovative therapies for cardiovascular diseases.
Latest news from Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States
September 3, 2026
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
September 2, 2026
Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes
August 27, 2026
Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)
August 21, 2026
Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update
August 12, 2026
Events
Research Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc. company profile
View the public company page for Milestone Pharmaceuticals Inc. on 6ix.
Milestone Pharmaceuticals Inc. news
Read company news and market updates connected to Milestone Pharmaceuticals Inc..
Milestone Pharmaceuticals Inc. investor events
Find investor webinars, events, and replay context for Milestone Pharmaceuticals Inc..